Grab it!
Optimised MTX management from the market leader1
WELCOME TO OUR SPECIALIST PLATFORM
As market leader1, our goal is to continuously optimise the management of treatment with MTX – and in doing so to achieve further improvements in the quality of life for patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, psoriasis vulgaris and Crohn’s disease.
On our specialist platform, healthcare professionals can find study results, the latest information from guidelines along with other scientific background information concerning the use of methotrexate (MTX) to treat autoimmune diseases – as well as the use of our simplified metoject® PEN: GRAB IT!
Self-injection if patients are using the previous MTX PEN
Related Content
1 IQVIA MIDAS Quarterly Sales Audit from Q2 2019 to Q4 2022